Alibaba Health Information Technology Limited
0241
Clasificación en acciones
#3022
Alibaba Health Information Technology Limited, an investment holding company,... Alibaba Health Information Technology Limited, an investment holding company, engages in the pharmaceutical direct sales, pharmaceutical e-commerce platform, and healthcare and digital services businesses in Mainland China and Hong Kong. The company offers a range of prescription and over-the-counter drugs, nutritional supplements, medical devices, contact lenses, healthcare food, adult and family planning products, and various other health-related products. It also provides medical and healthcare services, including medical checkups, medical consultation, appointment-booking, vaccination, dental and mental care, optometry, and nursing services, as well as traditional chinese medicines. The company provides products and services to business-to-customer and business-to-business customers through offline pharmacy outlets, as well as online stores, such as Tmall, Taobao, Alipay, Ele.me, AMap, DingTalk, Freshippo, and Quark. In addition, it engages in the digital tracking business; asset management; network hospital, software technical services, healthcare related internet information and technical services and research; operation of internet hospitals, as well as Alibaba Health, flagship platform of Alibaba Group for integrated online and offline medical and healthcare resources, providing one-stop healthcare solutions. The company was formerly known as CITIC 21CN Company Limited and changed its name to Alibaba Health Information Technology Limited in September 2014. Alibaba Health Information Technology Limited was incorporated in 1998 and is based in Causeway Bay, Hong Kong.
Precio por acción
$0.37546349
Capitalización bursátil
$6.07B
Cambio (1 día)
-3.77%
Cambio (1 año)
-52.40%
País
HK
Comercio Alibaba Health Information Technology Limited (0241)
Categoría
Healthcare
Ratio P/E de Alibaba Health Information Technology Limited (0241)
Ratio P/E al October 2026 TTM: 20.75
Según los últimos informes financieros y el precio de las acciones de Alibaba Health Information Technology Limited, el P/E actual (TTM) de la empresa es 20.75. Al final de 2024, la empresa tenía un P/E de 45.22.
Historial del ratio P/E de Alibaba Health Information Technology Limited desde 2004 hasta 2026
Relación P/E al final de cada año
| Año | Ratio P/E | Cambiar |
|---|---|---|
| 2026 (TTM) | 20.75 | -57.88% |
| 2025 | 49.27 | 8.94% |
| 2024 | 45.22 | -63.88% |
| 2023 | 125.22 | -160.00% |
| 2022 | -208.70 | -129.63% |
| 2021 | 704.30 | -103.28% |
| 2020 | -21.44K | 2,011.22% |
| 2019 | -1.02K | 279.53% |
| 2018 | -267.62 | 119.20% |
| 2017 | -122.09 | -27.23% |
| 2016 | -167.77 | -67.80% |
| 2015 | -521.04 | -84.11% |
| 2014 | -3.28K | 8,214.77% |
| 2013 | -39.45 | -82.87% |
| 2012 | -230.32 | 46.15% |
| 2011 | -157.59 | 25.02% |
| 2010 | -126.05 | 3,538.25% |
| 2009 | -3.46 | -85.86% |
| 2008 | -24.49 | -46.94% |
| 2007 | -46.17 | -107.88% |
| 2006 | 586.00 | 28.82% |
| 2005 | 454.91 | -128.53% |
| 2004 | -1.59K | 0.00% |
Relación P/E para empresas similares o competidores
| Empresa | P/E Ratio | Diferencia del P/E Ratio | País |
|---|---|---|---|
| 19.68 | -5.20% |
US
|
|
| 64.40 | 210.31% |
AU
|
|
| 44.30 | 113.46% |
US
|
|
| -47.78 | -330.20% |
US
|
|
| -123.90 | -696.99% |
US
|
¿Cómo leer un P/E ratio?
El ratio Precio/Beneficio (P/E Ratio) mide la relación entre el precio de las acciones de una empresa y sus beneficios por acción.
Un P/E bajo pero positivo indica una empresa con altos beneficios en relación a su valoración actual y que podría estar infravalorada. Una empresa con un P/E negativo alto (cerca de 0) indica fuertes pérdidas en comparación con su valoración.
Las empresas con un P/E superior a 30 o negativo suelen considerarse "acciones de crecimiento", lo que significa que los inversores esperan que crezca o se vuelva rentable en el futuro.
Las empresas con un P/E positivo inferior a 10 suelen considerarse "acciones de valor", lo que significa que ya son muy rentables y no se espera un fuerte crecimiento.